Introduction
To be able to understand the mechanisms of action of drugs, predict their efficacy, and anticipate their potential side-effects is important during drug development. In diseases where the genetic background of patients modulates treatment response, it allows personalizing the therapy.
Methods
We have developed computational methods to analyze unbiased drug target profiles, measured by chemical proteomics, which we applied to kinase inhibitors. Chemical proteomics pulldows are affinity purification methods that measure compound-protein interactions and they have revealed that kinase inhibitors can be promiscuous compounds [1,2], hence motivating a system-wide analysis approach. We were able to correlate chemical pulldown data with disease models constructed on the basis of known causative genes by means of diffusion processes, e.g. random walks (Fig. 1) . In the case of chronic myeloid leukemia (CML), this allowed us to predict very likely immunosuppressive effects of bosutinib and new indications for CML drugs.
Recently, in still unpublished work, we measured the protein target profiles of four kinase inhibitors in two Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) cell lines. We obtained predictions of treatment efficacy in reasonable agreement with experimentally determined IC 50 values and therefore we able to recommend the most successful therapy from in silico models.
Discussion
Altogether, our work aims at developing techniques able to implement personalized medicine therapies by combining detailed knowledge on drug profiles and patient specific genetic background. 
